← The patent line

Acetaminophen; Ibuprofen Sodium

Sold as COMBOGESIC IV · given by intravenous

Five to ten years until it comes off patent
9.4 yr
Until anyone may copy it
Protection runs to 2036-01-14
8
Trials running now
2091 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Hikma Pharmaceuticals Usa Inc
Approval holder
the only company permitted to sell it today
2036-01
Last patent expires
latest patent filed against this product
2026-10
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

PainPostoperative PainAnalgesia
03

Who is paying for the research

Ain Shams University
University or hospital
3
GlaxoSmithKline
Company
2
Seoul National University Hospital
University or hospital
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07721571No trials on record2026 · 60 people · recruiting now
Nephrostomy Tract Infiltration for Pain Cont

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line